Singer, A.
McClung, M. R.
Tran, O.
Morrow, C. D.
Goldstein, S.
Kagan, R.
McDermott, M.
Yehoshua, A.
Funding for this research was provided by:
Amgen
Article History
Received: 1 April 2022
Accepted: 20 February 2023
First Online: 11 March 2023
Declarations
:
: All database records are statistically de-identified and certified to be fully compliant with US patient confidentiality requirements set forth in the Health Insurance Portability and Accountability Act of 1996. Because this study used only de-identified patient records and did not involve the collection, use, or transmittal of individually identifiable data, this study was exempted from Institutional Review Board approval.
: • Michele McDermott declares the following conflict of interest: Dr. McDermott is employed by Amgen Inc.• Alon Yehoshua declares the following conflict of interest: At the time of manuscript development, Dr. Yehoshua was employed by Amgen Inc.• Cynthia Morrow declares the following conflict of interest: Dr. Morrow was employed by Merative, formerly IBM Watson Health, which received funding from Amgen Inc. to conduct this study.Oth Tran declares at the time of manuscript development, Mr. Tran was employed by Merative, formerly IBM Watson Health, which received funding from Amgen Inc. to conduct this study.• Michael McClung declares the following conflict of interest: Dr. McClung receives consulting fees and honorarium from Amgen Inc.• Andrea Singer declares the following conflict of interest: Dr. Singer receives research funding paid to her institution by Radius Health and UCB. Dr. Singer serves on consulting/advisory boards for Agnovos, Amgen Inc., Radius Health, and UCB. Dr. Singer is on the Speaker’s Bureau for Amgen Inc. and Radius Health.• Dr. Goldstein and Dr. Kagan declare they have no conflicts of interest.